Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diffuse large cell lymphoma.

B Coiffier1

  • 1Hematology Service, Hôspices Civils de Lyon, Lyon, France. bertrand.coiffier@chu-lyon.fr

Current Opinion in Oncology
|September 14, 2001
PubMed
Summary
This summary is machine-generated.

This review covers diffuse large B-cell lymphomas, focusing on classification, genetics, treatments, and specific sites. Understanding its heterogeneity is key to improving patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Diffuse large B-cell lymphoma (DLBCL), 2 versus 3: end of a debate?

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Involvement of the BCL2 Gene in 131 Cases of Non-Hodgkin's B Lymphomas: Analysis of Correlations with Immunological Findings and Cell Cycle.

Leukemia & lymphoma·2016
Same author

Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous non-Hodgkin lymphoma.
  • Its heterogeneity contributes to variable clinical characteristics and patient outcomes.
  • A significant portion of DLBCL may arise from the transformation of an indolent lymphoma.

Purpose of the Study:

  • To review emerging concepts in diffuse large B-cell lymphomas.
  • To emphasize key areas including classification, prognostics, and treatment strategies.
  • To discuss DLBCL in specific anatomic locations.

Main Methods:

  • Literature review of new and emerging ideas.
  • Focus on histologic classification and genetic prognostic factors.
  • Analysis of first-line and salvage treatment approaches.

Related Experiment Videos

Main Results:

  • DLBCL exhibits significant heterogeneity in clinical presentation and prognosis.
  • Genetic factors play a crucial role in predicting patient outcomes.
  • Treatment strategies are evolving for both initial and salvage settings.
  • Specific sites like the central nervous system, skin, and gastrointestinal tract present unique challenges.

Conclusions:

  • The heterogeneity of DLBCL, potentially linked to indolent lymphoma transformation, necessitates tailored therapeutic approaches.
  • Advances in understanding genetic factors and treatment modalities are crucial for improving DLBCL management.
  • Further research into site-specific DLBCL is warranted.